XML 60 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
License Agreements - Merus (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended 61 Months Ended
Jan. 31, 2022
item
Jan. 31, 2021
USD ($)
$ / shares
shares
Jan. 31, 2017
USD ($)
item
Dec. 31, 2016
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2021
USD ($)
License agreements                
Long term investments         $ 221,266 $ 222,301   $ 221,266
Research and development expense         1,458,179 2,215,942 $ 1,154,111  
Unrealized gain (loss) on long term investments         (24,072) 10,426 34,458  
Total revenues         2,986,267 2,666,702 2,158,759  
Net income (loss)         948,581 (295,697) 446,906  
Current assets         3,118,674 2,359,894   3,118,674
Current liabilities         854,308 631,195   854,308
Merus                
License agreements                
Number of independent programs | item     10          
Number of additional preclinical discovery programs | item 10              
Number of programs under the resulting products are co-funded for development | item 2              
Associated future global development costs , if elected to co-develop (as a percent) 35.00%              
Milestone payment made under license agreement               2,000
Merus | U.S.                
License agreements                
Profit sharing (as a percent)     50.00%          
Percentage of profit (losses)     50.00%          
Merus | Minimum                
License agreements                
Royalty payments on future global net sales (as a percent)     6.00%          
Merus | Minimum | U.S.                
License agreements                
Royalty payments on future global net sales (as a percent)     6.00%          
Merus | Maximum                
License agreements                
Royalty payments on future global net sales (as a percent)     10.00%          
Percentage of reverse royalty     4.00%          
Merus | Maximum | U.S.                
License agreements                
Royalty payments on future global net sales (as a percent)     10.00%          
Percentage of additional royalties     4.00%          
Merus | Maximum | Development and Regulatory Milestones                
License agreements                
Additional milestone payments under the license agreement     $ 100,000          
Merus | Maximum | Commercialization Milestones                
License agreements                
Additional milestone payments under the license agreement     $ 250,000          
Merus                
License agreements                
Fair market value of our long term investments         $ 112,900 56,100   $ 112,900
Ownership percentage (as a percent)         8.00%     8.00%
Unrealized gain (loss) on long term investments         $ 48,100 $ 11,000 $ 300  
Merus | IPO                
License agreements                
Common shares purchased (in shares) | shares   350,000            
Number of shares in underwritten public offering (in shares) | shares   4,848,485            
Per share price | $ / shares   $ 24.75            
Value of shares acquired   $ 8,700            
Merus | Stock purchase agreement                
License agreements                
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares       3,200,000        
Purchase price of common stock       $ 80,000        
Per share price | $ / shares       $ 25.00